Arctic Bioscience gave a status update related to the submission of the Clinical Trial Application (CTA) for a Phase IIb clinical trial in mild-to-moderate psoriasis with the investigational medicinal product (IMP) HRO350. Arctic Bioscience announce that the CTA has been submitted. Approval of CTA by authorities will allow for the first patient to be enrolled in the Phase IIb clinical trial as planned in Fourth Quarter 2022.

Sites for the clinical trial with access to sufficient number of patients to conduct the studies are localized in five European countries.